Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON47747
NL-OMON47747
Completed
Not Applicable

Validation of the Dutch version of the Hip Outcome Score - Dutch Validation HOS

Reinier de Graaf Groep0 sites136 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Reinier de Graaf Groep
Enrollment
136
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Trial ended prematurely

Registry
who.int
Start Date
TBD
End Date
March 19, 2021
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Reinier de Graaf Groep

Eligibility Criteria

Inclusion Criteria

  • •Patients who:
  • •\- are 18\-65 years of age
  • •\- have physical examination and radiological examination suspect for FAI
  • •\- Inclusion will not interfere with standard care for FAI
  • •\- provided informed consent
  • •\- understand the Dutch language

Exclusion Criteria

  • •Patients who:
  • •\- have had prior surgery to the hip for FAI
  • •\- have pathological fracture or other metastatic pathology
  • •\- refuse to particpatie
  • •\- do not speak the Dutch language

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta ThalassemiaBeta Thalassemiainherited blood disorder10038158
NL-OMON54921IMARA, Inc.15
Completed
Not Applicable
*Dutch Marines study on Rabies antibody response after Boostering an intradermal pre-exposure scheme (MaRaBoo study)*Rabies10047438
NL-OMON45312Academisch Medisch Centrum24
Completed
Phase 2
A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome
NL-OMON48225Millendo Therapeutics SAS23
Completed
Not Applicable
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Myeloid Malignanciesbeenmergstoornis: MDS (myelodysplastisch syndroom/myelodysplasie)Acute myeloid leukemiacancer of the bloodmyelodysplastic Syndrome10024324
NL-OMON55859Amgen10
Completed
Not Applicable
A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NL-OMON49382AbbVie B.V.2